RPI ID: 2022-060-301
Innovation Summary: This technology describes peptide ligands engineered for the affinity capture of nucleic acids, including DNA and RNA, in solution. These ligands are designed to bind selectively to nucleic acid targets, enabling efficient isolation and purification. The method includes synthesis and screening of peptide sequences with high binding specificity. It supports scalable bioprocessing and diagnostic workflows where nucleic acid capture is critical.
Challenges / Opportunities: Current nucleic acid capture methods often rely on antibodies or chemical tags, which can be costly or lack specificity. This invention offers a peptide-based alternative that is easier to produce and customize. It opens opportunities for improving workflows in genomics, molecular diagnostics, and therapeutic manufacturing. The approach also supports integration into automated and high-throughput systems.
Key Benefits / Advantages: ✔ High specificity for nucleic acid targets ✔ Scalable peptide synthesis and screening ✔ Compatible with solution-phase capture ✔ Supports diagnostics and biomanufacturing ✔ Cost-effective alternative to antibody-based methods
Applications: • Nucleic acid purification in diagnostics and therapeutics
Keywords: Peptide ligands, nucleic acid capture, RNA purification, DNA isolation, bioprocessing
Intellectual Property: WO2024258992A2 (Application PCT/US2024/033648), Published June 12, 2024